Novartis announces retirement of oncology head

Novartis has announced that Bruno Strigini, chief executive officer (CEO) of its Novartis Oncology business, will be leaving the company.

Mr Strigini has decided to retire from Novartis and the industry for personal reasons, having served in his current role since July 2016. He will step away from the executive committee of Novartis by December 31st, with a full handover of duties expected in early 2018.

The former president of Merck Sharp and Dohme in Europe and Canada, Mr Strigini first joined Novartis in 2014 in the role of oncology president. Other prior employers include Schering-Plough, UCB Celltech and SmithKline Beecham.

Novartis has confirmed that the outgoing executive's successor will be named in due course, while taking the opportunity to thank Mr Strigini for his contributions and achievements over the years.

Joseph Jimenez, chief executive officer of Novartis, said: "He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GlaxoSmithKline oncology product portfolio acquired in 2015."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.